deoxycytidine
Small moleculeexperimental
Deoxycytidine is a deoxyribonucleoside, a component of deoxyribonucleic acid. It is similar to the ribonucleoside cytidine, but with one hydroxyl group removed from the C2' position. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 13, 2015 (NCT02423057)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Acute Febrile Encephalopathy · Phase 2
- Bone Marrow Failure Disorders · Phase 1
- Cerebellum · Phase 1
- DNA, Mitochondrial · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Dyskeratosis Congenita · Phase 1
- Leukemia · Phase 1
- Lung Diseases, Interstitial · Phase 1
- Lymphoma · Phase 1
- Metabolism · Phase 2
- Mitochondrial Diseases · Phase 2
- Mitochondrial Encephalomyopathies · Phase 2
- Mitochondrial Myopathies · Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Neutrophils · Phase 1
- Pulmonary Fibrosis · Phase 1
- Telomere · Phase 1
- Thymidine Kinase · Phase 2
Mechanism of action
- DNA polymeraseBLOCKER
POL blocker
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDeoxycytidine ↗
Also known as
- deoxycytidine
- deoxycytidine
- tdcyd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02423057 | Phase 1 | Apr 13, 2015 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1